Poster Session 1: Clinical Cellular Therapy
Poster Abstracts
Longhorn Hall E (Exhibit Level 1) (Gaylord Texan)
The Clinical and Financial Cost of Preemptive Management of CMV Disease – Implications for Immunotherapy
Natasha A Jain, MD, National Heart, Lung, and Blood Institute;
Sawa Ito, M.D, National Heart, Lung, and Blood Institute;
Pawel Muranski, M.D., Ph.D., National Heart, Lung, and Blood Institute;
Kit Lu, M.D., National Heart, Lung, and Blood Institute;
Jan Haggerty, R.N., National Heart, Lung, and Blood Institute;
Catalina Ramos, BSN, National Heart, Lung, and Blood Institute;
Lisa Cook, National Heart, Lung, and Blood Institute;
Christopher S. Hourigan, MD, PhD, National Heart, Lung, and Blood Institute;
Richard Childs, MD, National Heart, Lung, and Blood Institute;
Minoo Battiwalla, MD, MS, National Heart, Lung, and Blood Institute;
A. John Barrett, MD, National Heart, Lung, and Blood Institute
[18F]-Fhbg-PET/CT Imaging of CD34-TK75+ T Cells in Allogeneic HSCT Recipients after Donor Lymphocyte Infusion (IND#11917; Clinicaltrials.Gov Identifier: NCT00871702)
Linda G. Eissenberg, PhD, Washington University School of Medicine;
Michael P. Rettig, PhD, Washington University School of Medicine;
Julie K. Ritchey, BS, Washington University School of Medicine;
Robert Fulton, PhD, Washington University School of Medicine;
Farrokh Dehdashti, MD, Washington University School of Medicine;
David Piwnica-Worms, MD, PhD, M.D. Anderson;
John F. DiPersio, MD, PhD, Washington University School of Medicine
Cell Separation System for Fully Automated Clinical Scale Separation of CD34+ Cells from Leukapheresis Products
Mike Essl, PhD, Miltenyi Biotec GmbH;
Juliane Stuth, Miltenyi Biotec GmbH;
Kristina Reck, MSc, Miltenyi Biotec GmbH;
Volker Huppert, Miltenyi Biotec GmbH;
Nanette von Oppen, PhD, Miltenyi Biotec GmbH;
Dirk Balshüsemann, PhD, Miltenyi Biotec GmbH;
Gerd Steffens, PhD, Miltenyi Biotec GmbH;
Juergen Schmitz, PhD, Miltenyi Biotec GmbH
T-Rapa6 and T-Rapa12 Cells Differentially Mediate Acute Gvhd after Low-Intensity Allogeneic HCT
David Halverson, MD, NCI;
Scott Rowley, MD, Hackensack University Medical Center;
Brenna Hansen, RN, NCI;
Bazetta Blacklock Schuver, RN, NCI;
Miriam Mossoba, PhD, NCI;
Seth Steinberg, PhD, National Cancer Institute, NIH;
Fran Hakim, PhD, NCI;
Roger Kurlander, MD, NIH;
Juan Gea-Banacloche, MD, NCI;
Claude Sportes, MD, Georgia Regents University Cancer Center;
Nancy Hardy, MD,, NCI;
Dennis Hickstein, MD, NCI;
Steven Z. Pavletic, MD, National Cancer Institute;
Hanh Khuu, MD, NIH;
Luciano Castiello, NIH;
Marianna Sabatino, PhD, NIH;
David F. Stroncek, MD, National Heart, Lung and Blood Institute NHLBI;
Bruce Levine, PhD, University of Pennsylvania;
Carl H. June, MD, University of Pennsylvania;
Michele L. Donato, MD, Hackensack University Medical Center;
Andre Goy, MD, Hackensack University Medical Center;
Robert Korngold, PhD, Hackensack University Medical Center;
Andrew Pecora, MD, Hackensack University Medical Center;
Michael R. Bishop, MD, University of Chicago;
Ronald Gress, MD, NCI;
Daniel Fowler, MD, NCI
Extending the Option of CMV-Specific T Cells from the CMV-Seronegative Donor
Patrick J Hanley, PhD, Children's National Medical Center;
Sarah Nikiforow, MD PhD, Dana-Farber Cancer Institute;
Jan Melenhorst, BS, PhD, National Institutes of Health, National Heart, Lung, and Blood Institute;
Phillip Scheinberg, MD, Hospital Beneficência Portuguesa de São Paulo;
Barbara Savoldo, MD, PhD, Texas Children's Hospital;
Gianpietro Dotti, MD, Baylor College of Medicine;
Cliona M. Rooney, PhD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Helen E. Heslop, MD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital;
Elizabeth J. Shpall, MD, UT MD Anderson Cancer Center;
A. John Barrett, MD, National Heart, Lung, and Blood Institute;
Catherine M. Bollard, MD, Children's National Medical Center
Generation and Characterization of a Third Party GMP Grade Bank of CMV Specific T-Cells for Adoptive Immunotherapy of CMV Infections in Recipients of HSCT from Cord Blood or Seronegative Donors
Aisha Nasreen Hasan, MD, Memorial Sloan-Kettering Cancer Center;
Ekaterina S. Doubrovina, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Guenther Koehne, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Susan E. Prockop, MD, Memorial Sloan-Kettering Cancer Center;
Richard O'Reilly, MD, Memorial Sloan-Kettering Cancer Center
Dual-Specificity CAR+ T Cells to Target B-Cell Malignancies and Opportunistic Fungal Infection
Pappanaicken R Kumaresan, PhD, UT MD Anderson Cancer Center;
Pallavi R Manuri, PhD, UT MD Anderson Cancer Center;
Nathaniel D Albert, BS, UT MD Anderson Cancer Center;
Harjeet Singh, Ph.D., UT MD Anderson Cancer Center;
Brain Rabinovich, PhD, MD Anderson Cancer Center;
Janani Krishnamurthy, MD Anderson Cancer Center;
Sourindra N Maiti, MD Anderson Cancer Center;
Olivares Simon, MD Anderson Cancer Center;
Tiejuan Mi, MD Anderson Cancer Center;
Dean Lee, MD, MD Anderson Cancer Center;
Dimitrios P. Kontoyiannis, MD, UT MD Anderson Cancer Center;
Helen Huls, BS, UT MD Anderson Cancer Center;
Laurence J.N. Cooper, MD, PhD, UT MD Anderson Cancer Center
T Cells Expressing Cars Directed Against HLA-0201 –Rmf WT-1 Peptide Complex Can Effectively Eradicate WT1+ A0201+ Tumor Cells in-Vitro
Tzu-Yun Kuo, MS, Weill Cornell Graduate School of Medical Sciences;
Aisha Nasreen Hasan, MD, Memorial Sloan-Kettering Cancer Center;
Qi Zhao, PhD, Memorial Sloan-Kettering Cancer Center;
Annamalai Selvakumar, PhD, Sloan Kettering Inst Cancer Res;
Dimiter Tassev, PhD, Sloan-Kettering Institute;
Nai-Kong Cheung, MD, Memorial Sloan-Kettering Cancer Center;
Richard O'Reilly, MD, Memorial Sloan-Kettering Cancer Center
Development of a Unique Anti-AML Immune Therapy Consisting of Cord Blood HSCT and Cord Blood Stem Cell-Derived Dendritic Cell (CB-DC) Vaccination
Colin de Haar, PhD, UMC Utrecht;
Maud Plantinga, UMC Utrecht;
Nina Blokland, UMC Utrecht;
Lotte Spel, UMC Utrecht;
Marianne Boes, PhD, UMC Utrecht;
Stefan Nierkens, PhD, UMC Utrecht;
Jaap-Jan Boelens, MD, PhD, University Medical Center Utrecht
An Algorithm to Facilitate Successful and Cost Effective Hematopoietic Progenitor Cell (HPC) Harvests Based on Peripheral Blood HPC CD34 Counts
Ramakrishnan Parameswaran, MD MRCP FRCPath, Avera McKennan Hospital & University Health Center;
Leslie Cooper, MLS(ASCP) SBB, Avera McKennan Hospital and University Health Center;
Aireen Guzman, Avera McKennan Hospital and University Health Center;
Lacey Roberts, Avera McKennan Hospital and University Health Center;
Robin Lockhorst, PharmD, Avera McKennan Hospital and University Health Center;
Kelly McCaul, MD FRCPC, Avera McKennan Hospital & University Health Center
Refined/Accelerated T Cell Therapies for the Treatment of EBV+ Lymphomas
Serena Kimi Perna, MD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Minthran Ngo, PhD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Natalia Lapteva, PhD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Jun Ando, MD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Lisa Rollins, MS, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Oumar Diouf, BS, Cell Medica Ltd.;
Ann M. Leen, PhD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Juan F. Vera, MD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Vicky Torrano, BS, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Adrian P. Gee, PhD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Stephen Gottschalk, MD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Carlos A. Ramos, MD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Catherine M. Bollard, MD, Children's National Medical Center;
Helen E. Heslop, MD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Cliona M. Rooney, PhD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital
Evaluating the Effector Function of Individual CD19-Specific T Cells to Assess the Therapeutic Impact of a Manufactured Product
Harjeet Singh, Ph.D., UT MD Anderson Cancer Center;
Ivan Liadi, University of Houston;
Gabrielle Romain, Ph.D., University of Houston;
Navin Varadarajan, Ph.D., University of Houston;
Laurence J.N. Cooper, MD, PhD, UT MD Anderson Cancer Center
Familial Haploidentical (FHI) T-Cell Depleted (TCD) with T-Cell Addback Stem Cell Transplantation for Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359)
Julie-An Talano, MD, Children's Hospital of Wisconsin;
Carolyn Keever-Taylor, PhD, Medical College of Wisconsin;
Mark Walters, MD, Children's Hospital & Research Center, Oakland;
Shalini Shenoy, MD, Washington University, St. Louis Children's Hospital;
Theodore B Moore, MD, David Geffen School of Medicine at UCLA;
Susan K. Parsons, MD, MRP, Tufts Medical Center;
Cori Abikoff, MD, New York Medical College;
Allen J Dozor, MD, New York Medical College;
Deborah Friedman, MD, New York Medical College;
Ramanamoorthy Chitti, MD, New York Medical College;
Qiuhu Shi, PhD, New York Medical College;
Brenda Grossman, MD, Washington University;
Rona Weinberg, PhD, New York Blood Center;
Erin Morris, RN, BSN, New York Medical College;
Phyllis Brand, RN, MPH, New York Medical College;
Daniel Mangan, BS, New York Medical College;
Sandra Foley, RN, MSN, CPNP, New York Medical College;
Olga Militano, PharmD, New York Medical College;
Janet Ayello, MS, MT(ASCP), New York Medical College;
Mildred Semidei-Pomales, MS, New York Medical College;
Lee Ann Baxter-Lowe, PhD, UCSF;
Mitchell S. Cairo, MD, New York Medical College
Automated Production of Clinical-Grade CMV-Specific T Cells to Implement Immunotherapy at the Bedside
Priti Tewari, MD, UT MD Anderson Cancer Center;
Pappanaicken R Kumaresan, PhD, UT MD Anderson Cancer Center;
Matthew Figliola, BS, UT MD Anderson Cancer Center;
Helen Huls, BS, UT MD Anderson Cancer Center;
Kevin Longin, BS, Miltenyi Biotec, Inc.;
Katharina Ruhnke, BS, Miltenyi Biotech;
Richard E. Champlin, MD, UT MD Anderson Cancer Center;
Harjeet Singh, PhD, UT MD Anderson Cancer Center;
Laurence J.N. Cooper, MD, PhD, UT MD Anderson Cancer Center
